Navigation Links
Patient Advocates File FOIA Request to FDA on Avastin
Date:4/27/2011

WASHINGTON, April 27, 2011 /PRNewswire/ -- Leaders in the battle with the U.S. Food and Drug Administration to retain metastatic breast cancer (mbc) as an indication for the drug Avastin today filed a Freedom of Information Act ("FOIA") request with the FDA.

The filers include noted attorney David Rivkin, partner at the law firm Baker Hostetler (www.bakerlaw.com/davidbrivkinjr/), Frank Burroughs and Steven Walker on behalf of the Abigail Alliance for Better Access to Developmental Drugs (www.abigail-alliance.org) campaigners for increased access to experimental drugs and Terrence Kalley on behalf of Freedom of Access to Medicines (www.fameds.org), an organization dedicated to the right of women to retain Avastin as a medical option for mbc.

The filers are troubled by many actions of the FDA in its review of the drug Avastin, a drug relied upon by an estimated 17,500 women with incurable mbc.  Forty thousand American women die each year from metastatic breast cancer.  Many woman and their oncologists report great success with the drug, yet the FDA will remove the indication for mbc, subject to a final appeal by the drug's manufacturer on June 28th & 29th at the FDA's headquarters in Silver Spring, Maryland.

The FOIA request includes documents regarding the nominations, appointment, actions and communications of the Oncologic Drugs Advisory Committee (ODAC) that will hear the appeal. Even though this panel will render a life and death decision at the June hearings, no patients or their advocates are allowed to speak and many may not be able to attend as the FDA claims space limitations.

The FOIA request also seeks documents regarding the processes by which the FDA reached its conclusions regarding Avastin, the communications between the FDA and various outside parties, any discussions related to the costs of Avastin in the FDA review process, conflicts of interest by those party to the Avastin decision, and other relevant issues.

The filers also seek the scientific basis for the FDA's decision with document requests related to risk and benefit evaluation of Avastin, comparison of the risk / benefit of Avastin versus current approved drugs, the use of progression free survival as a primary end point in cancer drug evaluation and the FDA's criteria for evaluation of toxicity under its Accelerated Approval Process.

The European Medicines Agency's advisory board recommended on April 15th, 2011 expanded use for Avastin for mbc. This follows the National Comprehensive Cancer Network's (an organization of leading U.S. cancer centers treating 160,000 patients per year) second vote to confirm retaining Avastin for use with mbc. The FOIA request includes documents related to how the FDA's decision-making process reached the opposite conclusion on Avastin from these bodies.    

CONTACT:  Rachel Partain, +1-248-404-0722, socialmedia@aqabatech.com


'/>"/>
SOURCE Freedom of Access to Medicines
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for Asthma or Allergies without Trying First-Line Medications End Up Staying on the Medication
2. For Patients on Statins, Study Finds Filling 90 Day Supply Prescriptions through Mail Service Compared to Retail Pharmacy is Associated with Less Waste
3. LATEST Medical Introduces New Kind of Patient Information Web Site - LATESTBreastCancer.com
4. TeleTrackings Patient Flow Dashboard XT™ Stops Operational Problems Before They Start
5. FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
6. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
7. Robotic Couch Provides Extra Degree of Precision for Patients Undergoing Radiation Therapy for Cancer
8. Digital Assent Signs 100th PatientPad® Customer
9. Banner Health and Poudre Valley Health System Collaborate to Improve Patient Care in Northern Colorado
10. New Published Study Finds Masimo Noninvasive SpCO Effective for Screening Emergency Department Patients for Carbon Monoxide Poisoning
11. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced it has earned a spot ... 2017" list. The Company was ranked among 500 U.S. ... Employers and Healthcare Equipment and Services. The ... on an anonymous, independent survey of over 30,000 employees ...
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
(Date:5/8/2017)... NEW YORK , May 8, 2017 ... in the transition from fee for service reimbursement. Black ... April 2017. 1.       The Market for ... 77% of physician practices with 3 or ... Compliance Technology Solutions by Q4. "Given the magnitude of ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as ... production of the series is on hiking in American. Viewers can reconnect with America ... great benefits of hiking. , Many consumers have looked for an inventive new place ...
(Date:5/26/2017)... ... ... FAMILY-Our Journey to the Cross”: the personal journey of Bob Massey and his faith in ... authors, Bob and Margaret Massey. Bob Massey is small in stature but big in ... His love for others is apparent in all of his life decisions. , ...
(Date:5/26/2017)... ... ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack and the ... is the creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist ... Jane. Walter. Walter and Jane have three adult children and a granddaughter. ...
(Date:5/24/2017)... ... May 24, 2017 , ... In ... choosing the most appropriate instruments for research and understanding the basic principles that ... webinar will focus on innovations in stereo microscopy for brightfield and fluorescence typically ...
(Date:5/24/2017)... ... May 24, 2017 , ... NucleusHealth ™, ... has received U.S. Food and Drug Administration (FDA) 510(k) clearance for ... secure cloud platform for medical image management. At the core is patented streaming ...
Breaking Medicine News(10 mins):